Claims for Patent: 7,655,637

Summary for Patent: 7,655,637

Title:	N-pyrazole A.sub.2A receptor agonists
Abstract:	2-adenosine N-pyrazole compounds having the following formula: ##STR00001## wherein R.sup.1.dbd.CH.sub.2OH; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20; --CONR.sup.7R.sup.8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C .sub.1-3alkyl and OR.sup.20;R.sup.4 is hydrogen; R.sup.7 is selected from hydrogen, and C.sub.1-3alkyl; R.sup.8 is hydrogen; and R.sup.20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
Inventor(s):	Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee:	Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:	11/588,834
Patent Claims:	1. A compound having the following formula: ##STR00022## wherein R.sup.1.dbd.CH.sub.2OH; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20, --CONR.sup.7R.sup.8, and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C.sub.1-3alkyl and OR.sup.20; R.sup.4 is hydrogen; R.sup.7 is selected from hydrogen, and C.sub.1-3alkyl; R.sup.8 is hydrogen; and R.sup.20 is selected from hydrogen and methyl. 2. A method for stimulating coronary vasodilatation in a mammal in need thereof by administering to the mammal a therapeutically effective amount of the compound of claim 1. 3. The method of claim 2 wherein the mammal is a human. 4. The method of claim 2, wherein the therapeutically effective amount of the compound is sufficient to stress the heart and induce a coronary steal situation. 5. The method of claim 2, wherein the therapeutically effective amount of the compound is sufficient for imaging heart or coronary activity in the mammal. 6. The method of claim 2 wherein the compound is administered by iv bolus. 7. The method of claim 6 wherein the compound is administered in from about 10 to about 30 seconds. 8. A method of producing coronary vasodilatation without peripheral vasodilatation comprising administering a compound of claim 1 to a human in need thereof. 9. The method of claim 8 wherein the compound is administered by iv bolus. 10. The method of claim 8 wherein the compound is administered in from about 10 to about 30 seconds. 11. The method of claim 8, wherein the compound is administered in an amount that is sufficient for imaging heart or coronary activity. 12. A method of myocardial perfusion imaging of a human in need thereof, comprising administering a radionuclide and a compound of claim 1 to the human wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the compound. 13. The method of claim 12, wherein the amount of the compound is sufficient to stress the heart and induce a coronary steal situation. 14. The method of claim 12 wherein the compound is administered by iv bolus. 15. The method of claim 14 wherein the compound is administered in from about 10 to about 30 seconds. 16. The method of claim 12 wherein the compound is administered before the radionucleotide is administered. 17. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutical excipient. 18. The pharmaceutical composition of claim 17 wherein the pharmaceutical composition is in the form of a solution. 19. The pharmaceutical composition of claim 17 wherein the pharmaceutical composition is formulated for injection.